| Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates |
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $0.79 per share a year ago. |
zacks.com |
2025-05-08 23:00:44 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights |
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD Executing on global commercial infrastructure development and on track with preparations for first potential commercial launch in U.S. in 2026 Strong balance sheet supports execution across three late-stage clinical programs and commercial launch preparations with cash runway into mid-2027 SAN DIEGO , May 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the first quarter ended March 31, 2025, highlighting recent progress. "We continue to build on the consistent and reproducible data readouts from our platform across all three of our clinical programs for DMD44, DM1 and FSHD, and are executing on our transition to become a global commercial organization. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Participate in Upcoming Investor Conference |
SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. |
prnewswire.com |
2025-05-06 13:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 |
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. |
prnewswire.com |
2025-04-08 13:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? |
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-03 14:35:50 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Participate in Upcoming Investor Conference |
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations. |
prnewswire.com |
2025-04-01 13:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy |
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO , March 31, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the biomarker cohort in the Phase 1/2 FORTITUDE™ clinical trial of delpacibart braxlosiran (del-brax) in people living with facioscapulohumeral muscular dystrophy (FSHD). A total of 51 participants were enrolled in the FORTITUDE biomarker cohort. |
prnewswire.com |
2025-03-31 13:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 101,200 shares of its common stock and 50,900 restricted stock units ("RSUs") to sixteen (16) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2025-03-21 18:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial |
On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts Plan to present functional data in fourth quarter of 2025 Investor and analyst webcast event today at 8:00 a.m. ET SAN DIEGO , March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive del-zota topline data from the Phase 1/2 EXPLORE44® trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) demonstrating consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase as well as favorable safety and tolerability across the dose cohorts. |
prnewswire.com |
2025-03-17 09:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference |
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44 ® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m. |
prnewswire.com |
2025-03-12 18:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases |
SAN DIEGO , Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. "Rare Disease Day represents an important opportunity for all of us, including people living with rare diseases, their friends, family and caregivers, and advocacy organizations around the world, to spotlight the many challenges that rare diseases present in daily living," said Sarah Boyce, President and Chief Executive Officer at Avidity. |
prnewswire.com |
2025-02-28 11:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates |
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago. |
zacks.com |
2025-02-27 20:40:43 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights |
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 M ajor milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission Commercial preparations well underway in anticipation of three potential successive product launches for DMD, DM1 and FSHD starting in 2026 Phase 1/2 EXPLORE44 ® top-line del-zota data to be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the fourth quarter ended December 31, 2024, highlighting recent progress and reiterating 2025 catalysts for its three clinical programs. "Successful readouts from our three clinical-stage programs in 2024 demonstrate the consistent and reproducible data of our AOC platform. |
prnewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Participate in Upcoming Investor Conferences |
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00 p.m. |
prnewswire.com |
2025-02-25 11:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,000 shares of its common stock and 53,500 restricted stock units ("RSUs") to twenty-two (22) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2025-02-21 18:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 10,500 shares of its common stock and 5,250 restricted stock units ("RSUs") to one (1) new non-executive employee under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2025-01-20 18:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common stock and 40,000 restricted stock units ("RSUs") to Charles Calderaro III, under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"), in connection with Mr. Calderaro's hiring and appointment as Avidity's Chief Technical Officer. |
prnewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 |
Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025 On track to complete enrollment in del-desiran HARBOR TM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025 Eric Mosbrooker expands role to Chief Commercial Officer; Charles Calderaro III, Chief Technical Officer, and Kat Lange, Chief Business Officer, join as company prepares for global commercialization and continued pipeline expansion Avidity to present at 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its progress and planning for a transformational year in 2025. |
prnewswire.com |
2025-01-08 11:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 720,400 shares of its common stock and 276,200 restricted stock units ("RSUs") to thirty-seven (37) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2024-12-20 19:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases |
Avidity Biosciences' AOC platform targets genetic diseases by combining monoclonal antibodies with oligonucleotide therapies, overcoming traditional delivery limitations. Del-brax (AOC 1020) for FSHD showed a 50% reduction in DUX4 gene expression, positioning it as a potential best-in-class therapy. Del-desiran (AOC 1001) for DM1 cleared the FDA's clinical hold, enabling progression to Phase 3 HARBOR trials with favorable regulatory designations. |
seekingalpha.com |
2024-12-11 11:25:13 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Participate in Upcoming Investor Conference |
SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: 7th Annual Evercore ISI HealthCONx Conference on December 3 at 9:30 a.m. PT / 12:30 p.m. |
prnewswire.com |
2024-11-26 12:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on November 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 117,000 shares of its common stock and 58,500 restricted stock units ("RSUs") to twelve (12) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2024-11-21 18:05:00 |
Czytaj oryginał (ang.) |
| RNA Stock Hits Record High on Entering the Cardiac Disease Space |
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies. |
zacks.com |
2024-11-14 11:41:18 |
Czytaj oryginał (ang.) |
| Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News |
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News appeared first on Investor's Business Daily. |
investors.com |
2024-11-13 13:24:41 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations |
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA Avidity introduces next-generation technology innovations demonstrating improved siRNA delivery in skeletal muscle and increased durability in preclinical studies AOC 1072 preclinical data will be presented at American Heart Association (AHA) Scientific Sessions 2024 Volume 11 of virtual investor and analyst series today, Tuesday, Nov. 12 at 8:00 a.m. ET SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart. |
prnewswire.com |
2024-11-12 09:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates |
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago. |
zacks.com |
2024-11-07 21:10:25 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights |
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. "We are executing three potentially registrational clinical trials in three rare diseases where there are limited or no therapeutic options available. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for |
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-06 13:05:28 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 |
Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will share new development candidates from its precision cardiology portfolio and provide a first look at its next-generation technology innovations. |
prnewswire.com |
2024-10-31 11:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 421,600 shares of its common stock and 210,800 restricted stock units ("RSUs") to thirty-four (34) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2024-10-21 20:05:00 |
Czytaj oryginał (ang.) |
| Why Avidity Biosciences Zoomed to a 12% Gain This Week |
The company's most promising pipeline program can continue unabated. |
fool.com |
2024-10-04 23:00:02 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Participate in Upcoming Investor Conference |
SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. |
prnewswire.com |
2024-09-25 13:00:00 |
Czytaj oryginał (ang.) |
| Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases |
Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates. |
benzinga.com |
2024-09-24 18:15:49 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 212,000 shares of its common stock and 106,000 restricted stock units ("RSUs") to twenty-one (21) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). |
prnewswire.com |
2024-09-23 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024 |
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. |
247wallst.com |
2024-09-08 11:43:58 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month |
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) SAN DIEGO , Sept. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining with patient and advocacy communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families who are impacted by neuromuscular diseases. |
prnewswire.com |
2024-09-05 13:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences to Participate in Upcoming Investor Conferences |
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. |
prnewswire.com |
2024-08-28 13:00:00 |
Czytaj oryginał (ang.) |
| Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO , Aug. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 52,100 shares of its common stock and 26,050 restricted stock units ("RSUs") to seven (7) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). |
prnewswire.com |
2024-08-21 20:05:00 |
Czytaj oryginał (ang.) |